Edgewise Therapeutics promotes Behrad Derakhshan to COO

Edgewise Therapeutics, Inc.

Behrad Derakhshan, Ph.D., appointed Chief Operating Officer effective January 8, 2025.
Previously served as Chief Business Officer since September 2020.
Annual base salary increased from $478,400 to $520,000; target bonus raised to 45%.
No family relationships with any director or executive officer of the company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Behrad Derakhshan

Chief Operating Officer

EWTX · Edgewise Therapeutics, Inc.

Effective: 2025-01-08
Filed: January 22, 2025, 6:59 PM ET

On January 8, 2025, the Board of Directors (the “ Board ”) of Edgewise Therapeutics, Inc. (the “ Company ”) promoted Behrad Derakhshan, Ph.D. to the role of Chief Operating Officer of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Behrad Derakhshan changed role as Chief Operating Officer at Edgewise Therapeutics, Inc..

Action: promoted
Role: Chief Operating Officer

Exact text from the filing

On January 8, 2025, the Board of Directors (the “ Board ”) of Edgewise Therapeutics, Inc. (the “ Company ”) promoted Behrad Derakhshan, Ph.D. to the role of Chief Operating Officer of the Company, effective immediately.

View on SEC.gov

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-005075

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.